Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Products for clotting factor replacement in developing countries.

Carol K Kasper1

  • 1University of Southern California, Los Angeles, California, USA. ckasper@laoh.ucla.edu

Seminars in Thrombosis and Hemostasis
|November 9, 2005
PubMed
Summary

Developing countries offer hemophilia treatment through domestic plasma, contract fractionation, or imported concentrates. Careful selection and program organization are key for effective resource use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A.

Genes and immunity·2025
Same author

A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A.

Genes and immunity·2025
Same author

Hemophilia: a cautionary status report.

Blood·2016
Same author

The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics.

Blood·2014
Same author

Inhibitors of factor VIII in black patients with hemophilia.

The New England journal of medicine·2009
Same author

Advances in care of children with hemophilia.

Seminars in thrombosis and hemostasis·2004

Area of Science:

  • Hematology
  • Public Health
  • Global Health

Background:

  • Developing countries face challenges in providing clotting factor replacement for hemophilia patients.
  • Existing strategies include domestic plasma production, domestic fractionation, contract fractionation, and concentrate importation.

Purpose of the Study:

  • To review and compare different strategies for clotting factor replacement in developing countries.
  • To highlight key considerations for establishing successful national hemophilia programs.

Main Methods:

  • Review of current practices for clotting factor replacement in resource-limited settings.
  • Analysis of the advantages and disadvantages of four distinct supply strategies.

Main Results:

Related Experiment Videos

  • Domestic plasma/cryoprecipitate offers self-sufficiency but relies on robust transfusion services and carries infection risks.
  • Domestic fractionation can be costly and may face patient distrust; contract fractionation balances self-sufficiency with plasma sourcing.
  • Importation provides product choice but necessitates focus on safety (donor testing, viral inactivation) over high purification.

Conclusions:

  • No single strategy is universally optimal; the choice depends on country-specific resources and infrastructure.
  • Successful hemophilia care requires integrated programs addressing organization, dosing, and equitable resource distribution.